Diabetes mellitus, largely type 2, affects nearly 10% of the global adult population according to the World Health Organization. Diabetes is an independent risk factor for atherosclerotic cardiovascular diseases, including coronary artery disease. Diabetes patients experience a two to three-fold increased incidence of coronary artery disease, despite improved metabolic control and management of other cardiovascular risk factors.
Discussion
Platelet abnormalities and activation as well as reduced antiplatelet drug responsiveness characterise diabetes mellitus. Mechanisms linking diabetes to platelet and vascular abnormalities, atherogenesis and atherosclerotic cardiovascular disease are still only partially known, highlighting the unique complexity of the pro-atherogenic clinical scenario and its treatment. Consistently, a higher residual cardiovascular risk characterises patients with diabetes compared with those without, in spite of improved antiplatelet and antithrombotic treatment combinations. Randomised clinical trials aimed at optimising antiplatelet treatment specifically in patients with diabetes are lacking, both in acute and chronic coronary artery disease settings. Thus, patients with diabetes are treated with regimens validated in studies including only variable proportions of diabetes patients. Myocardial revascularisation appears to confer a comparable relative benefit between diabetes patients and patients without diabetes, and generally coronary artery bypass grafting has a better outcome in diabetes mellitus versus peripheral coronary intervention. New glucose-lowering drugs have been shown to reduce the incidence of major cardiovascular events in secondary prevention. Type 1 diabetes mellitus remains less explored than type 2 in this context.
Conclusion
Diabetes-tailored antithrombotic strategies in acute and chronic coronary artery disease remain an unmet clinical need, requiring ad-hoc trials and precision pharmacological strategies.
ZaccardiFWebbDRYatesT, et al.Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J2016; 92: 63–69.
2.
PalumboPJElvebackLRChuCP, et al.Diabetes mellitus: incidence, prevalence, survivorship, and causes of death in Rochester, Minnesota, 1945–1970. Diabetes1976; 25: 566–573.
3.
Cosentino F, Grant P, Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for Diabetes, Pre-Diabetes, and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. Epub ahead of print 31 August 2019. DOI: 10.1093/eurheartj/ehz486.
4.
RawshaniARawshaniASattarN, et al.Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation2019; 139: 1900–1912.
5.
NathanDM. for the DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care2014; 37: 9–16.
6.
GersteinHCShahR. Cardiovascular outcomes trials of glucose-lowering drugs or strategies in type 2 diabetes. Endocrinol Metab Clin North Am2018; 47: 97–116.
7.
RawshaniARawshaniAFranzenS, et al.Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med2017; 376: 1407–1418.
8.
ZaccardiFRoccaBPitoccoD, et al.Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. Diabetes Metab Res Rev2015; 31: 402–410.
9.
Gkaliagkousi E, Nikolaidou B, Gavriilaki E, et al. Increased erythrocyte- and platelet-derived microvesicles in newly diagnosed type 2 diabetes mellitus. Diab Vasc Dis Res 2019; 16: 458–465.
10.
SchaferAWidderJEigenthalerM, et al.Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose. Thromb Haemost2004; 92: 97–103.
11.
BrownASHongYde BelderA, et al.Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol1997; 17: 802–807.
12.
ZaccardiFRoccaBRizziA, et al.Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: a case–control study. Nutr Metab Cardiovasc Dis2017; 27: 902–909.
13.
LeeRHBergmeierW. Sugar makes neutrophils RAGE: linking diabetes-associated hyperglycemia to thrombocytosis and platelet reactivity. J Clin Invest2017; 127: 2040–2043.
14.
FidlerTPCampbellRAFunariT, et al.Deletion of GLUT1 and GLUT3 reveals multiple roles for glucose metabolism in platelet and megakaryocyte function. Cell Rep2017; 21: 1705–1705.
15.
ZaccardiFRizziAPetrucciG, et al.In vivo platelet activation and aspirin responsiveness in type 1 diabetes. Diabetes2016; 65: 503–509.
16.
DaviGCatalanoIAvernaM, et al.Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med1990; 322: 1769–1774.
17.
KearneyKTomlinsonDSmithK, et al.Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol2017; 16: 34–34.
18.
Ten Cate H and Hemker HC. Thrombin generation and atherothrombosis: what does the evidence indicate? J Am Heart Assoc 2016; 5: 1–8.
19.
DaviGPatronoC. Platelet activation and atherothrombosis. N Engl J Med2007; 357: 2482–2494.
20.
SpectreGArnetzLOstensonCG, et al.Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost2011; 106: 491–499.
21.
RoccaBSantilliFPitoccoD, et al.The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost2012; 10: 1220–1230.
22.
ErlingeDVarenhorstCBraunOO, et al.Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol2008; 52: 1968–1977.
23.
LundstromALaskaACVon ArbinM, et al.Glucose intolerance and insulin resistance as predictors of low platelet response to clopidogrel in patients with minor ischemic stroke or TIA. Platelets2014; 25: 102–110.
24.
ZaccardiFPitoccoDWilleitP, et al.Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. Atherosclerosis2015; 240: 439–445.
25.
KentDMSteyerbergEvan KlaverenD. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ2018; 363: k4245–k4245.
26.
KuliczkowskiWGasiorMPresD, et al.Effect of glycemic control on response to antiplatelet therapy in patients with diabetes mellitus and ST-segment elevation myocardial infarction. Am J Cardiol2012; 110: 331–336.
27.
LettinoMLeonardiSDe MariaE, et al.Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. Eur J Prev Cardiol2017; 24: 61–70.
28.
PatronoCMoraisJBaigentC, et al.Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol2017; 70: 1760–1776.
29.
YusufSZhaoFMehtaSR, et al.Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med2001; 345: 494–502.
30.
WiviottSDBraunwaldEAngiolilloDJ, et al.Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation2008; 118: 1626–1636.
31.
JamesSAngiolilloDJCornelJH, et al.Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J2010; 31: 3006–3016.
32.
Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. Epub ahead of print 1 September 2019. DOI: 10.1056/NEJMoa1908077.
33.
VranckxPValgimigliMJuniP, et al.Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet2018; 392: 940–949.
34.
LeadbeaterPDKirkbyNSThomasS, et al.Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. J Thromb Haemost2011; 9: 2050–2056.
35.
ScavoneMFemiaEACaroppoV, et al.Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2. Eur Heart J2016; 37: 3347–3356.
36.
SibbingDAradiDJacobshagenC, et al.Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet2017; 390: 1747–1757.
37.
ColletJPCuissetTRangeG, et al.Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med2012; 367: 2100–2109.
38.
SpertusJAKettelkampRVanceC, et al.Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation2006; 113: 2803–2809.
39.
CutlipDEKereiakesDJMauriL, et al.Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv2015; 8: 404–410.
40.
ZanchinTTemperliFKaragiannisA, et al.Frequency, reasons, and impact of premature ticagrelor discontinuation in patients undergoing coronary revascularization in routine clinical practice: results from the Bern Percutaneous Coronary Intervention Registry. Circ Cardiovasc Interv2018; 11: e006132–e006132.
41.
AroraSShemisaKVaduganathanM, et al.Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC Review Topic of the Week. J Am Coll Cardiol2019; 73: 2454–2464.
42.
NeumannFJSousa-UvaMAhlssonA, et al.2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J2019; 40: 87–165.
43.
SilvainJVignalouJBBarthelemyO, et al.Coronary revascularization in the diabetic patient. Circulation2014; 130: 918–922.
44.
Task Force on Diabetes Pre-Diabetes, Cardiovascular Diseases of the European Society of Cardiology, European Association for the Study of Diabetes, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – summary. Diab Vasc Dis Res 2014; 11: 133–173.
45.
KappeteinAPHeadSJMoriceMC, et al.Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg2013; 43: 1006–1013.
46.
HakeemAGargNBhattiS, et al.Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data. J Am Heart Assoc2013; 2: e000354–e000354.
47.
Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002; 324: 71–86.
48.
MeredithITTanguayJFKereiakesDJ, et al.Diabetes mellitus and prevention of late myocardial infarction after coronary stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation2016; 133: 1772–1782.
49.
BhattDLBonacaMPBansilalS, et al.Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol2016; 67: 2732–2740.
50.
EikelboomJWConnollySJBoschJ, et al.Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017; 377: 1319–1330.
51.
ConnollySJEikelboomJWBoschJ, et al.Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet2018; 391: 205–218.
52.
FaggioniMBaberUSartoriS, et al.Incidence, patterns, and associations between dual-antiplatelet therapy cessation and risk for adverse events among patients with and without diabetes mellitus receiving drug-eluting stents: results from the PARIS Registry. JACC Cardiovasc Interv2017; 10: 645–654.
53.
Juul-MollerSEdvardssonNJahnmatzB, et al.Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet1992; 340: 1421–1425.
54.
DaviesMJD’AlessioDAFradkinJ, et al.Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia2018; 61: 2461–2498.
55.
ZelnikerTAWiviottSDRazI, et al.Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation2019; 139: 2022–2031.
56.
NauckMAMeierJJCavenderMA, et al.Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation2017; 136: 849–870.
57.
HeerspinkHJPerkinsBAFitchettDH, et al.Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation2016; 134: 752–772.
58.
ZelnikerTABraunwaldE. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art Review. J Am Coll Cardiol2018; 72: 1845–1855.
American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2019. Diabetes Care2019; 42: S103–S123.
61.
LevineGNBatesERBittlJA, et al.2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg2016; 152: 1243–1275.
62.
MegaJLBraunwaldEWiviottSD, et al.Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med2012; 366: 9–19.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
